We have located links that may give you full text access.
Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology.
Ophthalmology 2000 December
OBJECTIVE: This document describes photodynamic therapy (PDT) with verteporfin for age-related macular degeneration (AMD) and examines the evidence to answer the key question about whether the treatment is safe and effective in reducing visual loss from AMD.
METHODS: A literature search that was conducted in April 2000 retrieved eight relevant citations, and the reference lists of these articles were consulted for additional citations. Panel members reviewed this information, and a methodologist reviewed and rated all articles according to the strength of evidence.
RESULTS: The published literature contains a report of the combined results from two identically designed, double-masked randomized controlled trials. Ninety-four percent of participants completed the one-year follow-up. Patients treated with verteporfin had a decreased risk of at least moderate visual loss over this one-year period, but the beneficial effect on visual acuity was greatest among eyes in which the area of classic choroidal neovascularization (CNV) occupied 50% or more of the entire lesion area. There was no statistically significant difference in visual acuity outcomes at one year for yees in which the classic CNv was more than 0% but less than 50% of the area of the entire lesion. Serious systemic complications were rare. Severe vision decrease (equivalent to four lines or more of vision) within 7 days of treatment with verteporfin has been reported in 1% to 4% of patients. Partial recovery of vision was observed in many of these patients.
CONCLUSIONS: To date, evidence suggests that PDT using verteporfin can reduce the risk of visual loss in patients with predominantly classic subfoveal CNV from AMD at one year. The rate of ocular and systemic complications is low. Additional clinical research is needed to determine the long-term effectiveness of treatment and the comparitive effectiveness with existing and new treatment modalities under investigation.
METHODS: A literature search that was conducted in April 2000 retrieved eight relevant citations, and the reference lists of these articles were consulted for additional citations. Panel members reviewed this information, and a methodologist reviewed and rated all articles according to the strength of evidence.
RESULTS: The published literature contains a report of the combined results from two identically designed, double-masked randomized controlled trials. Ninety-four percent of participants completed the one-year follow-up. Patients treated with verteporfin had a decreased risk of at least moderate visual loss over this one-year period, but the beneficial effect on visual acuity was greatest among eyes in which the area of classic choroidal neovascularization (CNV) occupied 50% or more of the entire lesion area. There was no statistically significant difference in visual acuity outcomes at one year for yees in which the classic CNv was more than 0% but less than 50% of the area of the entire lesion. Serious systemic complications were rare. Severe vision decrease (equivalent to four lines or more of vision) within 7 days of treatment with verteporfin has been reported in 1% to 4% of patients. Partial recovery of vision was observed in many of these patients.
CONCLUSIONS: To date, evidence suggests that PDT using verteporfin can reduce the risk of visual loss in patients with predominantly classic subfoveal CNV from AMD at one year. The rate of ocular and systemic complications is low. Additional clinical research is needed to determine the long-term effectiveness of treatment and the comparitive effectiveness with existing and new treatment modalities under investigation.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app